SC plus Simple Convergence Exercises (SC+) for Opsoclonus
Interventions for Convergence Insufficiency in Concussed Children
See full descriptionAbout the trial for Opsoclonus
Treatment Groups
This trial involves 3 different treatments. SC Plus Simple Convergence Exercises (SC+) is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
Eligibility
This trial is for patients born any sex aged 18 and younger. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether SC plus Simple Convergence Exercises (SC+) will improve 1 primary outcome and 7 secondary outcomes in patients with Opsoclonus. Measurement will happen over the course of 12 weeks.
Patient Q & A Section
What is opsoclonus?
We hypothesize that opsoclonus might have many causes, and its diagnosis is still difficult. We need more research to discuss its definition and its characteristics.
How many people get opsoclonus a year in the United States?
As many as half of the US population have clinically significant OSA at some point in their life. In a study of over 10,000 patients, OSA was found in 50% of patients who experienced one or more episodes of focal dystonia in a 3-year period. It is thus likely that some individuals with focal dystonia who are found to have OSA will be untreated. OSA, a possible cause of focal dystonia, requires further investigation. Copyright © 2016 John Wiley & Sons, Ltd.
Can opsoclonus be cured?
There are many treatments that can produce long-term, complete, and/or sustained remission including: \n- [Immunosuppressive agents as (iv) prednisolone]\n- plasmapheresis\n- pulse therapy (iv) with prednisone\n- intravenous immunoglobulin,\n- [Oligodendrocytes-transplanted patients (iv)]\n- intrathecal-based medications (injectable) such as ziconotide and r-baclofen.
What causes opsoclonus?
This is the first report mentioning Opsoclonus as a cause of opsoclonus (the first report using Opsoclonus as a cause of Opsoclonus was previous to the report this article). This article may contribute to a better understanding of Opsoclonus.
What are common treatments for opsoclonus?
This report on the use of levetiracetam and propranolol for opsoclonus suggests that they may have a role in management and possibly prolonging the duration of opsoclonus with some patients treated off medication.
What are the signs of opsoclonus?
Ophthalmologic examination is helpful in establishing the diagnosis of opsoclonus, the treatment depends on the underlying causes. Neurological examination remains to be the only means of diagnosing opsoclonus.
What does sc plus simple convergence exercises (sc+) usually treat?
SC plus simple exercise therapy should be considered and is effective for the treatment of SC plus simple-convergence dystonia and sc + OI, because the combination was more effective and less dangerous for the patients than SC alone.
Have there been any new discoveries for treating opsoclonus?
There is still a need for new methods of treatment of opsoclonus. There are many new treatments of opsoclonus. These are mainly non-surgical. The use of anticholinergic agents has been proven to be successful in this condition. It has proven successful over the past fifteen years as well. New drugs for the treatment of opsoclonus including gabapentin (Neurotrend, Neurontin), amitriptyline (Syndrome, Celexa), and topiramate have been used as other non-surgical treatments for this condition as well. There have been new treatments being developed, tested and used.
Have there been other clinical trials involving sc plus simple convergence exercises (sc+)?
There have been other clinical trials on sc+ for treatment of some conditions but this is the first to report the effects and the number of subjects of a sc+ treatment programme for SCID-CID.
How serious can opsoclonus be?
In about 80% of patients with this autonomic disorder, signs and symptoms improve or disappear over months or years, although not all patients are completely free of symptoms. Therefore, the most important factor in treatment is not the degree of symptoms but how they affect the patient's life. Although, as yet, no conclusive explanation of the nature of the disorder has been found, the development of new medications to manage attacks and improved understanding of the genetics and physiology of autonomic disorders may allow more effective treatment of opsoclonus.
Does sc plus simple convergence exercises (sc+) improve quality of life for those with opsoclonus?
The improvement in QOL for those with OOS is clinically meaningful in that it will provide an additional benefit to all. This added benefit was greater than the change from baseline and may be due to the combination of the sc plus exercises alone or a combination of sc and sc. More research will be required to clarify this.